Literature DB >> 32946819

Draft FDA guidance for assessing the safety of glucose lowering therapies: a missed opportunity?

Kamlesh Khunti1, Melanie J Davies2, Nikolaus Marx3, John B Buse4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32946819     DOI： 10.1016/S2213-8587(20)30302-8

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  1 in total

1.  Non-inferiority and clinical superiority of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes.

Authors:  Francesco Zaccardi; David E Kloecker; Kamlesh Khunti; Melanie J Davies
Journal:  Diabetes Obes Metab       Date:  2022-05-29       Impact factor: 6.408
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.